Sangamo Therapeutics, INC
SEC CIK 1001233 · SGMO · last insider filing 2026-05-27
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Macrae Sandy | Director · President, CEO and Director | filed 2016 - 2026 |
| Parker H Stewart | Director | filed 2014 - 2025 |
| Horn Margaret A | Director | filed 2022 - 2025 |
| Meyers James R | Director | filed 2019 - 2025 |
| Hillan Kenneth J. | Director | filed 2020 - 2025 |
| Carey Robert | Director | filed 2016 - 2025 |
| Smith Karen L. | Director | filed 2018 - 2025 |
| Markels John | Director | filed 2020 - 2025 |
| Beers Courtney | Director | filed 2022 - 2025 |
| Zakrzewski Joseph S | Director | filed 2017 - 2022 |
| Ramasastry Saira | Director | filed 2012 - 2022 |
| Dilly Stephen George | Director | filed 2010 - 2020 |
| Jeffs Roger | Director | filed 2017 - 2018 |
| Mento Steven J | Director | filed 2006 - 2018 |
| Ringo William R | Director | filed 2010 - 2017 |
| Lanphier Edward O II | Director · President & Chief Exec Officer | filed 2006 - 2017 |
| Wolff Henry Ward | Director · Executive VP and CFO | filed 2006 - 2016 |
| Cleveland Paul B | Director | filed 2008 - 2016 |
| Larson John William | Director | filed 2006 - 2015 |
| Wiggans Thomas G | Director | filed 2008 - 2011 |
| Gerber William G | Director | filed 2006 - 2010 |
| Wood Michael C | Director | filed 2006 - 2008 |
| Liu Margaret | Director | filed 2006 - 2008 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Willoughby Scott B. | SVP, Gen. Counsel & Secretary | filed 2021 - 2026 |
| Dubois-Stringfellow Nathalie | SVP-Chief Development Officer | filed 2022 - 2026 |
| Davis Gregory D | Head of Research & Technology | filed 2024 - 2026 |
| Jain Nikunj | Principal Accounting Officer | filed 2025 - 2026 |
| Duraibabu Prathyusha | Vice President, Finance | filed 2019 - 2026 |
| Pooler Amy | VP, Head of Research | filed 2023 - 2024 |
| Mcclung David Mark | EVP, Chief Operating Officer | filed 2020 - 2023 |
| Fontenot Jason D. | SVP, Chief Scientific Officer | filed 2021 - 2023 |
| Ramelmeier Rolf Andrew | EVP, Technical Operations | filed 2019 - 2023 |
| Schott Robert J. | SVP, Head of Development | filed 2021 - 2022 |
| Loeb Gary | EVP, General Counsel & Sec. | filed 2019 - 2021 |
| Lee Sung | EVP, Chief Financial Officer | filed 2019 - 2020 |
| Boissel Stephane | EVP, Corporate Strategy | filed 2018 - 2020 |
| Woolfson Adrian | EVP, Research and Development | filed 2019 - 2020 |
| Yi Kathy | Senior VP & CFO | filed 2017 - 2019 |
| Turner Heather D | SVP and General Counsel | filed 2018 - 2019 |
| Conner Edward R. | Sr. VP & Chief Medical Officer | filed 2016 - 2019 |
| Herberts Curt A. III | Sr.VP & Chief Business Officer | filed 2016 - 2018 |
| Ando Dale G | VP, Therapeutic Dev. & CMO | filed 2006 - 2015 |
| Nichol Geoffrey | Executive Vice President, R&D | filed 2011 - 2015 |
| Gregory Philip D | Vice President, Research & CSO | filed 2006 - 2015 |
| Ichikawa David G | Senior VP, Bus. Dev. | filed 2006 - 2011 |
| Zante Greg | Vice President, Fin. & Admin. | filed 2006 - 2008 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.